PFIZER INC — Director's Dealing 2021

Mar 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2021-02-25

Reporting Person: DAMELIO FRANK A (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-25	Common Stock	M	163334.0000	$22.8900	Acquired	588584.0000	Direct
2021-02-25	Common Stock	F	28221.0000	$33.8200	Disposed	560363.0000	Direct
2021-02-25	Common Stock	F	105707.0000	$34.7600	Disposed	454656.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-25	Stock Appreciation Rights	$22.8900	M	163334.0000	Disposed	2021-02-25	Common Stock (163334.0000)	Direct
2021-02-25	Stock Appreciation Rights	$33.8200	A	210697.0000	Acquired	2026-02-25	Common Stock (210697.0000)	Direct
2021-02-25	Stock Appreciation Rights	$33.8200	A	182050.0000	Acquired	2028-02-25	Common Stock (182050.0000)	Direct

Footnotes

F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

F5: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F6: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.